Совершенствование терапии лимфобластных неходжкинских лимфом у подростков и молодых взрослых
Диссертация
Лимфобластная лимфома (ЛБЛ) — относительно редкий вариант неходжкинских лимфом (НХЛ) высокой степени злокачественности с характерными цитологическими, гистологическими и клиническими признаками. Первое морфологическое описание «медиастинального лейкосаркоматоза», завершившегося развитием острого лейкоза, было представлено Штенбергом в 1916 г. Позднее, в 1932 г. Куки опубликовал критический обзор… Читать ещё >
Список литературы
- Алексеева Ю.А., Зарицкий А. Ю., Медведева Н. В. и др. Применение дексаметазона при неходжкинских лимфомах высокой и низкой степени злокачественности. Вопросы онкологии. 2004−50(6):726−728.
- Виноградова Ю.Е., Луценко И. Н., Кременецкая A.M. и др. Нозологические формы и выживаемость больных T/NK-клеточными лимфатическими опухолями. Гематология и трансфузиология. 2009−4:3−9.
- Езерский Д.В., Канин B.C., Молоствова В. З. Случай развития острой почечной недостаточности при лимфобластной лимфосаркоме. Проблемы гематологии и переливания крови. 1997−3:39−42.
- Карачунский А. И. Стратегия терапии острого лимфобластного лейкоза у детей. Автореф. дисс. .докт. мед. наук. М., 1999.
- Карачунский А.И., Румянцева Ю. В., Румянцев А. Г. Эволюция лечения острого лимфобластного лейкоза у детей: критическое использование мирового опыта в России. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 201.1- 10(2): 15−31.
- Ковынев И.Б., Лосева М. И., Поспелова Т. И. и др. Иммуноморфологические варианты лимфобластных неходжкинских лимфом у взрослых и детей. Вестник гематологии 2006−2(3): 16−21.
- Криволапое Ю. А. Морфологическая дифференциальная диагностика лимфом из клеток-предшественников. Гематология и трансфузиология. 2007−5:32−38.
- Маякова С.А., Попа A.B., Морозова О. В. и др. Современные подходы к диагностике и терапии лимфоидных опухолей у детей. Педиатрия. 2009−4:15−19.
- Поддубная И. В. Обоснование лечебной тактики при неходжкинских лимфомах. Современная онкология 2002−1:23−27.
- Ю.Румянцев А. Г., Масчан A.A., Самочатова Е. В., Чернов В. М. Детская гематология в России: достижения и перспективы развития. Педиатрия. 2009−4:9−14.
- Самочатова Е.В., Алейникова О. В., Беликова Л. Ю. и др. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии по данным клиник России и Беларуси. Проблемы гематологии и переливания крови 2001 — 1:3−10.
- Самочатова Е.В. Неходжкинские лимофмы. В книге «Гематология/онкология детского возраста», под. ред. Румянцева А. Г. Самочатовой E.B. М.: Медпрактика: 2004. — 780 с.
- Самочатова Е.В., Островская A.B., Карачунский А. И. и др. Значение верификации варианта неходжкинских лимфом у детей для эффективности лечения по современным протоколам. Гематология и трансфузиология. 2000−45(6):9−14.
- Семочкин C.B., Лория С. С., Румянцев А. Г. и др. Опыт терапии подростков и взрослых больных с неходжкинскими лимфомами по педиатрическому протоколу NHL-BFM-90m. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2007−6(4): 18−26.
- Семочкин C.B., Оптимизация технологий лечения лимфопролиферативных заболеваний у подростков и лиц молодого возраста. Автореферат на соискание ученой степени доктора медицинских наук. М., 2008.
- Сергиенко В.И., Бондарева И. Б. Математическая статистика в клинических исследованиях. М. Гэотар-медицина, 2001. — 256 с.
- Щербакова Е.О., Ватазин А. В., Столяревич Е. С. и др. Острая почечная недостаточность как первое проявление первичной лимфомьі почек. Терапевтический архив. 2008−6:73−76.
- Ярилин А.А., Кветной И. М., Пальцев М. А., Полякова В. О. Молекулярная нейроиммунозндокринология тимуса. Молекулярная медицина.2006−4:3−13.
- Adelaide J., Perot C., Gelsi-Boyer V., et al. A t (8−9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia. 2006−20(3):536−537.
- Arima N., Matsushita K., Obata H., et al. NF-kappaB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol. 1999−27(7):1168−1175.
- Aster J.C., Pear W.S., Blacklow S.C. Notch signaling in leukemia. Annu Rev Pathol. 2008−3:587−613.
- Avellino R., Romano S., Parasole R., et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood. 2005−106(4):1400−1406.
- Baleydier F., Decouvelaere A.V., Bergeron J., et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008−14(3):692−700.
- Berg S.L., Blaney S.M., Devidas M., et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol. 2005−23:3376−3382.
- Bohlander S.K., Muschinsky V., Schrader K., et al. Molecular analysis of the * CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia. 2000−14:93−99.
- Borowitz M.J., Chan J.K.C. Precursor Lymphoid Neoplasms Book Section. // WHO classificatin of tumours of haematopoietic and lymphoid tissues. / book auth. Swerdlow S.H. Campo E., Harris N.L. et al. (Eds.). Lyon: IARC, 2008, p.167−178.
- Brown V.I., Seif A.E., Reid G.S., et al. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res. 2008−42:84−105.
- Burkhardt B., Bruch J., Zimmermann M., et al. Loss of heterozygosity on chromosome 6q 14−24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006−20:1422−1429.
- Cheng J.T., Cobb M.H., Baer R. Phosphorylation of the TALI oncoprotein by the extracellular-signal-regulated protein kinase ERK1. Mol Cell Biol. 1993−13(2):801−808.
- Chiarini F., Fala F., Tazzari P.L., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009−69(8):3520−3528.
- Conrad D.M., Robichaud M.R., Mader J.S., et al. 2-Chloro-2'-deoxyadenosine-induced apoptosis in T leukemia cells is mediated via a caspase-3-dependent mitochondrial feedback amplification loop. Int J Oncol. 2008−32(6): 1325−1333.
- Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 2008−33(3): 122−131.
- Cooke J.V. Mediastinal tumor in acute leukemia: a clinical and roentgenologic study. Am J Dis Child. 1932−44:1153−1177.
- Coustan-Smith E., Sandlund J.T., Perkins S.L., et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. Hematology Meeting Reports. 2009- 3(5): 11.
- Cox D.R. Regression models and life tables. Journal of the Royal Statistical Society 1972-Series B (34): 187−220.
- Cullion K., Draheim K.M., Hermance N., et al. Targeting the Notch 1 and mTOR pathways in a mouse T-ALL model. Blood. 2009- 113(24):6172−6181.
- Dabaja B.S., Ha C.S., Thomas D.A., et al. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma Cancer. 2002−94(10):2738−2744.
- Dudley E.C., Petrie H.T., Shah L.M., et al. T cell receptor beta chain gene rearrangement and selection during thymocyte development in adult mice. Immunity. 1994- 1(2):83−93.
- Ellisen L.W., Bird J., West D.C., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991−66(4):649−661.
- Ellison D.A., Parham D.M., Sawyer J.R. Cytogenetic findings in pediatric T-lymphoblastic lymphomas: one institution’s experience and a review of the literature. Pediatr Dev Pathol. 2005−8:550−556.
- Fan Q.W., Knight Z.A., Goldenberg D.D., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006−9(5):341−349.
- Flex E., Petrangeli V., Stella L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008−205(4):751−758.
- Fukuda R.I., Tsuchiya K., Suzuki K., et al. Human T-cell leukemia virus type I tax down-regulates the expression of phosphatidylinositol 3,4,5-trisphosphate inositol phosphatases via the NF-kappaB pathway. J Biol Chem. 2009−284(5):2680−2689.
- Gonzalez-Garcia S., Garcia-Peydro M., Martin-Gayo E., et al. CSL-MAML-dependent Notch 1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med. 2009−206(4):779−791.
- Graux C., Cools J., Michaux L., et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006−20:1496−1510.
- Han X., Bueso-Ramos C.E. Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol. 2007−127:528−544.
- Hashimoto M., Yamashita Y., Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002−197:341−347.
- Hochberg J., Waxman I.M., Kelly K.M., et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009−144(l):24−40.
- Hoelzer D., Gokbuget N. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma 2009- 9(Suppl 3): S214−221.
- Hoelzer D., Gokbuget N., Digel W., et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002−99(12):4379−4385.
- Hunault M., Truchan-Graczyk M., Caillot D., et al. Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica. 2007−92(12): 1623−1630.
- Jabbour E., Koscielny S., Sebban C., et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2006−20(5):814−819.
- Janssen J.W., Ludwig W.D., Sterry W., Bartam C.R. SIL-TAL1 deletion T-cell acute lymphoblastic leukemia. Leukemia. 1993−7-1204−1210.
- Jeon Y.K., Park C.H., Kim K.Y., et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol. 2007−213(2): 170−179.
- Joshi I., Minter L.M., Telfer J., et al. Notch signaling mediates Gl/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood. 2009−113(8):1689−1698.
- Juntilla M.M., Koretzky G.A. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett. 2008- 116(2): 104−110.
- Kahwash S.B., Qualman S.J. Cutaneous lymphoblastic lymphoma in children: report of six cases with precursor B-cell lineage. Pediatr. Dev Pathol. 2002−5(l):45−53.
- Kaneko Y., Frizzera G., Maseki N., et al. A novel translocation, t (9−17)(q34-q23), in aggressive childhood lymphoblastic lymphoma. Leukemia 1988−2:745−748.
- Kaneko Y., Frizzera G., Shikano T., et al. Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T ALL) and lymphoblastic lymphoma (LBL). Leukemia 1989−3:886−892.
- Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958−53:457−481.
- Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002−2(4):301−310.
- Kim S.W., Tanimoto T.E., Hirabayashi N., et al. Myeloablative allogeneic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood. 2006−108:382−389.
- Kordes U., Krappmann D., Heissmeyer V., et al. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000−14(3):399−402.
- Labar B., Suciu S., Willemze R., et al. Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients final results of the ALL-4 randomized, Phase III. Haematologica. 2010−95(9): 1489−1495.
- Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997−278(5341):1309−1312.
- Lambe C.U., Averett D.R., Paff M.T., et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995−55:3353−3356.
- Le Gouill S., Lepretre S., Briere J., et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia. 2003−17(ll):2220−2224.
- Lee J., Suh C., Kang H.J., et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 2008−19(12):2079−2083.
- Levine J., Harris R., Loberiza F., et al. A comparison of allogenic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003−101:2476−2482.
- Lin P. Jones D., Dorfman D.M., Medeiros L.J. Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol. 2000−24(11): 1480−1490.
- Link M.P., Donaldson S.S., Berard C.W. et al. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990−322:1169−1174.
- Link M.P., Shuster J J., Donaldson S.S., at al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med. 1997−337(18): 1259−1266.
- Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989−7:1630−1636.
- Lopez-Nieva P., Santos J., Fernandez-Piqueras J. Defective expression of Notch 1 and Notch2 in connection to alterations of c-Myc and Ikaros in gamma-radiation-induced mouse thymic lymphomas. Carcinogenesis. 2004−25(7): 1299−1304.
- Luo C., Burgeon E., Rao A. Mechanisms of transactivation by nuclear factor of activated T cells-1. J Exp Med. 1996−184(1):141−147.
- Macintype E Biology of T-cell lymphoblastic lymphoma. Hematology Meeting Reports. 2009- 3(5):32.
- Marafioti T., Pozzobon M., Hansmann M.L., et al. The NFATcl transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br J Haematol. 2005−128(3):333−342.
- Marzec M., Kasprzycka M., Ptasznik A., et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest. 2005−85(12): 1544−1554.
- Marzec M.3 Liu X., Kasprzycka M., et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORCl pathway in malignant CD4+ T lymphocytes. Blood. 2008- 111 (4):2181−2189.
- McCubrey J.A., Steelman L.S., Abrams S.L., et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3 K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008−22:708−722.
- McNeil L.K., Starr T.K., Hogquist K.A. A requirement for sustained ERK signaling during thymocyte positive selection in vivo. Proc Natl Acad Sci U S A. 2005- 102(38): 13 574−13 579.
- Medyouf H., Alcalde H., Berthier C., et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med. 2007- 13(6):736−741.
- Medyouf H., Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle. 2008−7(3):297−303.
- Meier C., Hoeller S., Bourgau C., et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol. 2009−22(3):476−487.
- Milpied N., Ifrah N., Kuentz M., et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haemat. 1989−73:82−87.
- Mitchell T.J., Whittaker S.J., John S. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. Cancer Res. 2003−63(24):9048−9054.
- Mora A.L., Stanley S., Armistead W., et al. Inefficient ZAP-70 phosphorylation and decreased thymic selection in vivo result from inhibition of NF-kappaB/Rel. J Immunol. 2001−167(10):5628−5635.
- Mora J., Filippa D.A., Qin J., Wollner N. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer. 2003−98(6):1283−1291.
- Moricke A., Zimmermann M., Reiter A., et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010−24(2):265−284.
- Murphy S.B. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980−7(3):332−339.
- Nachman J.B., Sather H.N., Sensel M.G., et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998−33 8:1663−1671.
- Naeem R., Singer S., Fletcher J.A. Translocation t (8−13)(pl l-ql 1−12) in stem cell leukemia/lymphoma of T-cell and myeloid lineages. Genes Chromosomes Cancer. 1995−12:148−151.
- Nasr R., El-Sabban M.E., Karam J.A., et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005−24(3):419−430.
- Navid F., Mosijczuk A.D., Head D.R., et al. Acute lymphoblastic leukemia with the (8−14)(q24-q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience. Leukemia. 1999−13:135−141.
- Neilson J.R., Winslow M.M., Hur E.M., Crabtree G.R. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity. 2004−20(3):255−266.
- Neth O., Seidemann K., Jansen P., et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000−35(l):20−27.
- O’Neil J., Shank J., Cuson N., et al. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 2004−5:587−596.
- Palomero T., Dominguez M., Ferrando A. A. The role of the PTEN/AKT Pathway in NOTCH 1-induced leukemia. Cell Cycle. 2008−7(8):965−970.
- Palomero T., Sulis M.L., Cortina M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007- 13(10): 1203−1210.
- Pear W.S., Aster J.C., Scott M.L., et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996- 183(5):2283−2291.
- Peto R., Peto J. Asymptotically efficient rank invariant procedures. Journal of the Royal Statistical Society 1972−135(Serial A):185−207.
- Petrie H. T-cell migration and the control of post-natal T-cell lymphopoiesis in the thymus. Nat Rev Immunol. 2003−3(11):859−866.
- Pilozzi E., Muller-Hermelink H.K., Falini B., et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol. 1999−188:267−270.
- Pilozzi E. Pulford K., Jones M. et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol. 1998−186:140−143.
- Radtke F., Wilson A., Mancini S.J., MacDonald H.R. Notch regulation of lymphocyte development and function. Nat Immunol. 2004−5(3):247−253.
- Recine M., Castellano-Sanchez A.A., Sheldon J., et al. Precursor B-cell lymphoblastic lymphoma/leukemia presenting as osteoblastic bone lesions. Ann Diagn Pathol. 2002−6(4):236−243.
- Reiter A. Current management of lymphoblastic lymphoma. Hematology Meeting Reports. 2009−3(5):32−33.
- Reiter A., Schrappe M., Ludwig W.D., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000−95(2):416−421.
- Reiter A., Schrappe M., Tiemann M., et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999−94(10):3294−3306.
- Robertson P.B., Neiman R.S., Worapongpaiboon S., et al. 013 (CD99) positivity in hematological proliferations correlates with TdT positivity. Mod Pathol. 1997- 10:277−282.
- Rodriguez C.O., Stellrecht C.M., Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003- 102(5): 1842−1848.
- Sabapathy K., Kallunki T., David J.P., et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. Exp Med. 2001- 193(3):317−328.
- Sandlund J.T., Pui C.H., Zhou Y., et al.: Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL 13 study. Leukemia 2009−23(6): 1127−1130.
- Schade A.E., Wlodarski M.W., Maciejewski J.P. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle. 2006−5(22):2571−2574.
- Schaeffer H.J., Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol. 1999−19(4):2435−2444.
- Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007−282(28):20 059−20 063.
- Schmidt-Supprian M., Tian J., Grant E.P., et al. Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. ProcNatl Acad Sci USA. 2004−101(13):4566−4571.109
- Sen J., Venkataraman L., Shinkai Y., et al. Expression and induction of nuclear factor-kappa B-related proteins in thymocytes. J Immunol. 1995- 154(7) :3213−3221.
- Serwold T., Hochedlinger K., Inlay M.A., et al. Early TCR expression and aberrant T cell development in mice with endogenous prerearranged T cell receptor genes. J Immunol. 2007−179(2):928−938.
- Silva A., Yunes J.A., Cardoso B.A., et al. PTEN posttranslational inactivation and hyperactivation of the РІЗК/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008- 118(11):3762−3774.
- Sommer V.H., Clemmensen O.J., Nielsen O., et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function, of STAT3. Leukemia. 2004−18(7):1288−1295.
- Song K.W., Barnett M.J., Gascoyne R.D., et al. Primary therapy for adult with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcome. Ann Oncol. 2007−18:535−540.
- Soslow R.A., Baergen R.N., Warnke R.A. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer. 1999−85(12):2648−2654.
- Stankunas K., Graef I.A., Neilson J.R., et al. Signaling through calcium, calcineurin, and NF-AT in lymphocyte activation and development. Cold Spring Harb Symp Quant Biol. 1999−64:505−516.
- Steelman L.S., Abrams S.L., Whelan J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008−22:686−707.
- Sternberg C. Leukosarkomatose und Myeloblastenleukamie. Beitr z Path Anatuzallg Path 1916−61:75−100.
- Sugawara T., Moriguchi T., Nishida E., Takahama Y. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity. 1998−9(4):565−574.
- Thomas D.A., O’Brien S., Cortes J., et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004- 104(6): 1624−1630.
- Torlakovic E., Torlakovic G., Nguyen P.L., et al. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002−26:1343−1350.
- Tubergen D.G., Krailo M.D., Meadows A.T., et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: A Childrens Cancer Group Study. J Clin Oncol. 1995−13:1368−1376.
- Turella P., Cerella C., Filomeni G., et al. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res. 2005−65(9):3751−3761.
- Vega F., Medeiros L.J., Leventaki V., et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006−66(13):6589−6597.
- Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002−2:489−501.
- Voakes J.B., Jones S.E., McKelvey E.M. The chemotherapy of lymphoblastic lymphoma. Blood. 1981−57:186−188.
- Wadman I.A., Hsu H.L., Cobb M.H., Baer R. The MAP kinase phosphorylation site of TALI occurs within a transcriptional activation domain. Oncogene. 1994−9(12):3713−3716.
- Wei G., Twomey D., Lamb J., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell-2006−10(4):331−342.
- Wei L., Laurence A., O’Shea J.J. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol. 2008−19(4):394−400.
- Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004−306(5694):269−271.
- Yap T.A., Garrett M.D., Walton M.I., et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008−8(4):393−412.
- Zhao Y.M., Zhou Q., Xu Y., et al. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 2008−29(4):481−488.
- Zhu Y.M., Zhao W.L., Fu J.F., et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res. 2006−12:3043−3049.
- Zinzani P.L., Musuraca G., Tani M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007−25(27):4293−4297.